Team-Based Care for Managing Cardiac Comorbidities in Heart Failure

Heart Failure Clinics

Volumn 11, Issue 3, 2015, Pages 407-417

  Bellam, Naveen ^a   Kelkar, Anita A ^b   Whellan, David J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Affiliate providers; Cardiac comorbidities; Heart failure; Management; Multidisciplinary; Team based

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; ATRIAL FIBRILLATION; CARDIAC RESYNCHRONIZATION THERAPY; CATHETER ABLATION; CLINICAL TRIAL (TOPIC); COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATION; EVIDENCE BASED PRACTICE; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LENGTH OF STAY; MULTICENTER STUDY (TOPIC); NURSE; NURSE PRACTITIONER; PATIENT CARE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACIST; PHYSICIAN; PHYSICIAN ASSISTANT; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TEAMWORK; TREATMENT OUTCOME; COST BENEFIT ANALYSIS; DISEASE MANAGEMENT; ECONOMICS; HOSPITALIZATION; ORGANIZATION AND MANAGEMENT; PROCEDURES;

COMORBIDITY; COST-BENEFIT ANALYSIS; DISEASE MANAGEMENT; HEART FAILURE; HOSPITALIZATION; HUMANS; PATIENT CARE TEAM; PATIENT-CENTERED CARE;

EID: 84937391993     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2015.03.005     Document Type: Review

References (66)

1. Heidenreich P.A., Albert N.M., Allen L.A., et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 2013, 6(3):606-619.
2. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. NEngl J Med 1999, 341(10):709-717.
3. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. NEngl J Med 2003, 348(14):1309-1321.
4. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013, 128(16):1810-1852.
5. Heart Failure Society of America, Lindenfeld J., Albert N.M., et al. HFSA 2010 comprehensive heart failure practice guideline. JCard Fail 2010, 16(6):e1-e194.
6. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353(9146):9-13.
7. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001, 357(9266):1385-1390.
8. Arandomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 1994, 90(4):1765-1773.
9. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007.
10. Travers B., O'Loughlin C., Murphy N.F., et al. Fluid restriction in the management of decompensated heart failure: no impact on time to clinical stability. JCard Fail 2007, 13(2):128-132.
11. Aliti G.B., Rabelo E.R., Clausell N., et al. Aggressive fluid and sodium restriction in acute decompensated heart failure: a randomized clinical trial. JAMA Intern Med 2013, 173(12):1058-1064.
12. Maisel W.H., Stevenson L.W. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003, 91(6 Suppl 1):2-8.
13. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JAm Coll Cardiol 2013, 62(16):e147-e239.
14. January C.T., Wann L.S., Alpert J.S., et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014, 130:2071-2104.
15. Tran H.N., Tafreshi J., Hernandez E.A., et al. Amultidisciplinary atrial fibrillation clinic. Curr Cardiol Rev 2013, 9(1):55-62.
16. January C.T., Wann L.S., Alpert J.S., et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. JAm Coll Cardiol 2014, 64(21):2246-2280.
17. Hendriks J.M., de Wit R., Crijns H.J., et al. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur Heart J 2012, 33(21):2692-2699.
18. Stewart S., Ball J., Horowitz J. Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial. Lancet 2014, 385. [pii:S0140-6736(14)61992-9].
19. Berti D., Hendriks J.M., Brandes A., et al. Aproposal for interdisciplinary, nurse-coordinated atrial fibrillation expert programmes as a way to structure daily practice. Eur Heart J 2013, 34:2725-2730.
20. Practice spotlight: pharmacists in a multidisciplinary atrial fibrillation clinic. Can J Hosp Pharm 2011, 64(5):370-371.
21. Chilipko A.A., Norwood D.K. Evaluating warfarin management by pharmacists in a community teaching hospital. Consult Pharm 2014, 29(2):95-103.
22. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. NEngl J Med 2002, 346(12):877-883.
23. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. NEngl J Med 2005, 352(3):225-237.
24. Grubman E.M., Pavri B.B., Shipman T., et al. Cardiac death and stored electrograms in patients with third-generation implantable cardioverter-defibrillators. JAm Coll Cardiol 1998, 32(4):1056-1062.
25. Chung M.K., Szymkiewicz S.J., Shao M., et al. Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. JAm Coll Cardiol 2010, 56(3):194-203.
26. Hohnloser S.H., Kuck K.H., Dorian P., et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. NEngl J Med 2004, 351(24):2481-2488.
27. Dougherty C.M., Thompson E.A., Lewis F.M. Long-term outcomes of a telephone intervention after an ICD. Pacing Clin Electrophysiol 2005, 28(11):1157-1167.
28. Naccarelli G.V., Luck J.C., Wolbrette D.L., et al. Pacing therapy for congestive heart failure: is it ready for prime time?. Curr Opin Cardiol 1999, 14(1):1-3.
29. Landolina M., Perego G.B., Lunati M., et al. Remote monitoring reduces healthcare use and improves quality of care in heart failure patients with implantable defibrillators: the evolution of management strategies of heart failure patients with implantable defibrillators (EVOLVO) study. Circulation 2012, 125(24):2985-2992.
30. Maron B.J., Towbin J.A., Thiene G., et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006, 113:1807-1816.
31. Elliott P., Andersson B., Arbustini E., et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008, 29(2):270-276.
32. Bart B.A., Shaw L.K., McCants C.B., et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. JAm Coll Cardiol 1997, 30(4):1002-1008.
33. Allman K.C., Shaw L.J., Hachamovitch R., et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. JAm Coll Cardiol 2002, 39(7):1151-1158.
34. Holper E.M., Blair J., Selzer F., et al. The impact of ejection fraction on outcomes after percutaneous coronary intervention in patients with congestive heart failure: an analysis of the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry and Dynamic Registry. Am Heart J 2006, 151(1):69-75.
35. O'Connor C.M., Velazquez E.J., Gardner L.H., et al. Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank). Am J Cardiol 2002, 90(2):101-107.
36. Ragosta M., Beller G.A., Watson D.D., et al. Quantitative planar rest-redistribution 201Tl imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass surgery in patients with severely depressed left ventricular function. Circulation 1993, 87(5):1630-1641.
37. Samady H., Elefteriades J.A., Abbott B.G., et al. Failure to improve left ventricular function after coronary revascularization for ischemic cardiomyopathy is not associated with worse outcome. Circulation 1999, 100(12):1298-1304.
38. Velazquez E.J., Lee K.L., Deja M.A., et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. NEngl J Med 2011, 364(17):1607-1616.
39. Bonow R.O., Maurer G., Lee K.L., et al. Myocardial viability and survival in ischemic left ventricular dysfunction. NEngl J Med 2011, 364(17):1617-1625.
40. Schinkel A.F., Poldermans D., Rizzello V., et al. Why do patients with ischemic cardiomyopathy and a substantial amount of viable myocardium not always recover in function after revascularization?. JThorac Cardiovasc Surg 2004, 127(2):385-390.
41. Sedlis S.P., Ramanathan K.B., Morrison D.A., et al. Outcome of percutaneous coronary intervention versus coronary bypass grafting for patients with low left ventricular ejection fractions, unstable angina pectoris, and risk factors for adverse outcomes with bypass (the AWESOME Randomized Trial and Registry). Am J Cardiol 2004, 94(1):118-120.
42. Gupta P.K., Gupta H., Sundaram A., et al. Development and validation of a risk calculator for prediction of cardiac risk after surgery. Circulation 2011, 124(4):381-387.
43. Goldman L., Caldera D.L., Nussbaum S.R., et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. NEngl J Med 1977, 297(16):845-850.
44. Wit M.A., Bos-Schaap A.J., Hautvast R.W., et al. Nursing role to improve care to infarct patients and patients undergoing heart surgery: 10 years' experience. Neth Heart J 2012, 20(1):5-11.
45. Hall M.H., Esposito R.A., Pekmezaris R., et al. Cardiac surgery nurse practitioner home visits prevent coronary artery bypass graft readmissions. Ann Thorac Surg 2014, 97(5):1488-1493. [discussion: 1493-5].
46. Levy D., Larson M.G., Vasan R.S., et al. The progression from hypertension to congestive heart failure. JAMA 1996, 275(20):1557-1562.
47. Piller L.B., Baraniuk S., Simpson L.M., et al. Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation 2011, 124:1811-1818.
48. Kalantar-Zadeh K., Block G., Horwich T., et al. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. JAm Coll Cardiol 2004, 43(8):1439-1444.
49. Granger C.B., McMurray J.J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362(9386):772-776.
50. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. NEngl J Med 1991, 325(5):293-302.
51. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. NEngl J Med 2004, 351:2049-2057.
52. Swenne C.A. Beyond lipid lowering: pleiotropic effects of statins in heart failure. Neth Heart J 2013, 21(9):406-407.
53. Horwich T.B., Hamilton M.A., Maclellan W.R., et al. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. JCard Fail 2002, 8(4):216-224.
54. Rauchhaus M., Koloczek V., Volk H., et al. Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol 2000, 76(2-3):125-133.
55. von Haehling S., Schefold J.C., Springer J., et al. The cholesterol paradox revisited: heart failure, systemic inflammation, and beyond. Heart Fail Clin 2008, 4(2):141-151.
56. Horwich T.B., MacLellan W.R., Fonarow G.C. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. JAm Coll Cardiol 2004, 43(4):642-648.
57. Liu G., Zheng X.X., Xu Y.L., et al. Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction. Am J Cardiol 2014, 113(7):1198-1204.
58. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. NEngl J Med 2007, 357(22):2248-2261.
59. Gissi H.F., Tavazzi L., Maggioni A.P., et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372(9645):1231-1239.
60. Jessup M., Abraham W.T., Casey D.E., et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119(14):1977-2016.
61. Albert N.M., Fonarow G.C., Yancy C.W., et al. Outpatient cardiology practices with advanced practice nurses and physician assistants provide similar delivery of recommended therapies (findings from IMPROVE HF). Am J Cardiol 2010, 105(12):1773-1779.
62. Driscoll A., Srivastava P., Toia D., et al. Anurse-led up-titration clinic improves chronic heart failure optimization of beta-adrenergic receptor blocking therapy: a randomized controlled trial. BMC Res Notes 2014, 7(1):668.
63. Henrick A. Cost-effective outpatient management of persons with heart failure. Prog Cardiovasc Nurs 2001, 16(2):50-56.
64. Branch R.D. ACHF clinic. How aggressive outpatient care can offset hospitalization. JAAPA 1999, 12(10):24-26. 29, 32 passim.
65. Dunagan W.C., Littenberg B., Ewald G.A., et al. Randomized trial of a nurse-administered, telephone-based disease management program for patients with heart failure. JCard Fail 2005, 11(5):358-365.
66. O'Connor C.M., Whellan D.J., Lee K.L., et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009, 301(14):1439-1450.